Cargando…

Renal Granulomatosis Post Intravesical Bacillus Calmette–Guerin Therapy for Non-muscle-invasive Bladder Cancer

Intravesical Bacillus Calmette–Guerin (BCG) immunotherapy is a proven, effective treatment for intermediate- and high-risk non-muscle-invasive bladder cancer. Minor side effects are common and expected but systemic effects can occur in <5% of treated patients. We present a rare case of a 49-year-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tran-Harding, Karen, Nair, Rashmi T, Ganesh, Halemane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5939034/ https://www.ncbi.nlm.nih.gov/pubmed/29770266 http://dx.doi.org/10.4103/jcis.JCIS_83_17

Ejemplares similares

Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
por: James, Christopher, et al.
Publicado: (2023)

Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity
por: Prasanna, Thiru, et al.
Publicado: (2017)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?
por: D’Andrea, David, et al.
Publicado: (2019)

Tuberculous Spondylitis following Intravesical Bacillus Calmette-Guerin for Bladder Cancer
por: Miyazaki, Masashi, et al.
Publicado: (2016)

Efficacy and toxicity of intravesical Bacillus Calmette-Guérin therapy in elderly patients with non-muscle-invasive bladder cancer
por: Matsuoka, Yuki, et al.
Publicado: (2021)

Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure
por: Shantharam, Govind, et al.
Publicado: (2021)

Renal Tuberculosis Following Intravesical Bacillus Calmette–Guérin (BCG) Immunotherapy for the Treatment of Bladder Cancer
por: Bajramovic, Senad, et al.
Publicado: (2020)

Predictive biomarkers of response to bacillus Calmette‐Guérin immunotherapy and bacillus Calmette‐Guérin failure for non‐muscle invasive bladder cancer
por: Wang, Ziting, et al.
Publicado: (2022)

Intravesical bacillus Calmette-Guerin for bladder cancer: What is known? What is not? What is next?
por: Madbouly, Khaled
Publicado: (2013)

Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer
por: Liu, Yuqing, et al.
Publicado: (2019)

Managing the adverse events of intravesical bacillus Calmette–Guérin therapy
por: Decaestecker, Karel, et al.
Publicado: (2015)

Tuberculous Spondylitis Caused by Intravesical Bacillus Calmette-Guerin Therapy
por: Minakata, Tomokazu, et al.
Publicado: (2020)

Reactive Arthritis After Intravesical Bacillus Calmette-Guérin Therapy
por: Taniguchi, Yoshinori, et al.
Publicado: (2022)

A severe complication of intravesical bacillus Calmette-Guerin: An effect of different strains
por: Low, Li Sian, et al.
Publicado: (2021)

Is Intravesical Bacillus Calmette-Guérin Therapy Superior to Chemotherapy for Intermediate-risk Non-muscle-invasive Bladder Cancer?: An Ongoing Debate
por: Han, Kyung-Sik, et al.
Publicado: (2015)

Combination of Intravesical Chemotherapy and Bacillus Calmette–Guerin Versus Bacillus Calmette–Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis
por: Cui, Jianfeng, et al.
Publicado: (2016)

Combination of Intravesical Bacille Calmette-Guérin and Chemotherapy vs. Bacille Calmette-Guérin Alone in Non-muscle Invasive Bladder Cancer: A Meta-Analysis
por: Huang, Di, et al.
Publicado: (2019)

AB152. Combination of intravesical chemotherapy and Bacillus Calmette-Guerin versus Bacillus Calmette-Guerin monotherapy in intermediate- and high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis
por: Cui, Jianfeng, et al.
Publicado: (2016)

Bladder Contracture – A Rare and Serious Side Effect of Intravesical Bacillus Calmette-Guérin Therapy
por: Garcia, Cindy, et al.
Publicado: (2015)

A Case of Systemic Toxicity Related to Intravesical Bacillus Calmette-Guerin for the Treatment of Bladder Cancer
por: Gupta, Sachin, et al.
Publicado: (2021)

Reiter’s syndrome following intravesical Bacillus Calmette-Guerin therapy for bladder carcinoma: Case report
por: Alsulami, Hajar Aown Allah, et al.
Publicado: (2023)

Intravesical Bacillus Calmette–Guérin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies
por: Miyake, Makito, et al.
Publicado: (2021)

Mycobacterium bovis spondylodiscitis after intravesical Bacillus Calmette-Guérin therapy
por: Obaid, Sami, et al.
Publicado: (2011)

Disseminated Granulomatous Disease from Intravesical Instillation of Bacillus Calmette-Guerin
por: Ghafouri, Sayed Ab. Reshad, et al.
Publicado: (2018)

Tuberculosis epididymo-orchitis following intravesical bacillus Calmette-Guérin immunotherapy
por: Rezvani, Sean, et al.
Publicado: (2019)

Miliary Tuberculosis that Developed after Intravesical Bacillus Calmette-Guerin Therapy
por: Kaburaki, Kyohei, et al.
Publicado: (2017)

Tuberculous prostatic abscess following intravesical bacillus Calmette-Guérin immunotherapy
por: Wang, Bin, et al.
Publicado: (2019)

Mycobacterial Infection after Intravesical Bacillus Calmette-Guërin Treatment for Bladder Cancer: A Case Report
por: Park, Chang-Hun, et al.
Publicado: (2011)

Is Bladder Tumor Location Associated with Prostate Cancer Detection after Intravesical Bacillus Calmette-Guérin Instillation?
por: Hong, Sungwoo, et al.
Publicado: (2014)

Bacillus Calmette–Guerin intravesical instillation therapy-induced urothelial necrosis of the bladder and upper urinary tract
por: Kondo, Tsubasa, et al.
Publicado: (2022)

Drug‐induced interstitial pneumonia after intravesical Bacillus Calmette‐Guerin administration for bladder cancer with scleroderma
por: Yoshioka, Fumie, et al.
Publicado: (2023)

Comparison of intravesical bacillus Calmette-Guerin and mitomycin C administration for non-muscle invasive bladder cancer: A meta-analysis and systematic review
por: JIANG, SHANG-JUN, et al.
Publicado: (2016)

Adjustments in the Use of Intravesical Instillations of Bacillus Calmette-Guérin for High-risk Non-muscle-invasive Bladder Cancer During the COVID-19 Pandemic
por: Lenfant, Louis, et al.
Publicado: (2020)

A Molecular Signature Determines the Prognostic and Therapeutic Subtype of Non-Muscle-Invasive Bladder Cancer Responsive to Intravesical Bacillus Calmette-Guérin Therapy
por: Kim, Seon-Kyu, et al.
Publicado: (2021)

Adjuvant intravesical chemohyperthermia or conventional chemotherapy in an era of bacillus Calmette-Guérin shortage for non-muscle invasive bladder cancer: The HIVEC-II trial
por: Bhargava, Priyank
Publicado: (2023)

Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer
por: McElree, Ian M., et al.
Publicado: (2023)

Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer
por: Suh, Jungyo, et al.
Publicado: (2020)

Emerging treatments for bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer
por: Kim, Hyung Suk, et al.
Publicado: (2021)

Treatment strategies for the Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder cancer
por: Jeong, Seung-hwan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_71io53hiukn7olkmud3q0mf983